Eagle's Eye View: Your Weekly CV Update From ACC.org

American College of Cardiology

The weekly cardiovascular update from Kim Eagle, MD, MACC for ACC.org covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.

Play

Open in

27 episodes
weekly
Avg 9 min
English

Episodes 27

Newest Oldest Longest

All20 Unplayed20 In progress0 Played0

Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.

Wednesday · 11 min
The new ACC Scientific Statement on Exercise Prescription for CV Health, Multimodality Cardiac Imagine, Risk Stratification & CMR, Preventive PCI and CV Risk
In this week's View, Dr. Eagle looks at the new ACC Scientific Statement on Exercise Prescriptions for Cardiovascular Health in Adults. He then examines a recent State-of-the-Art Review on the evolving role of multimodality cardiovascular imaging in the diagnosis and management of cardiac sarcoidosis (CS). He follows that with a look at a risk stratification model based on cardiac magnetic resonance (CMR) results. Finally, Dr. Eagle offers a summary of an analysis of the PREVENT trial on how preventive PCI lowers CV risk in patients with lipid-rich plaques. Subscribe to Eagle's Eye View
October 14 · 8 min
Sex Disparities in CV Trials; Left Stellate Ganglion Blocks & CABG; Bifurcation Lesions; Managing Resistant Hypertension
In this week's View, Dr. Eagle looks at continued sex disparities in CV clinical trials. He then examines how preemptive left stellate ganglion block (SGB) is associated with a reduced incidence of postoperative atrial fibrillation (POAF) in patients undergoing CABG. He follows that with a look at bifurcation lesions as analyzed in the OCTOBER Trial. Finally, Dr. Eagle offers a brief vignette on resistant hypertension and how to manage it.
October 7 · 8 min
ACC/AHA Joint Perioperative Guidelines; Atenolol and MACE Risk; Yoga and VPCs; DECIPHER and CMR
In this week's View, Dr. Eagle looks at how the most recent perioperative guideline published in 2024 remains valid and current. He then examines how, in the treatment of patients without recorded heart failure (HF), starting atenolol after a myocardial infarction (MI) was associated with a lower two-year risk of major adverse cardiovascular events (MACE), but not all-cause mortality. He follows that with a look at patients with frequent ventricular premature complexes (VPCs) and how a structured yoga program compared with standard care reduced VPCs as well as improved quality of life (QOL) and psychological burden. Finally, Dr. Eagle discusses the DECIPHER HFpEF Study on cardiac magnetic resonance (CMR) tissue mapping and its capture of active relaxation impairment (σ) and passive stiffness (β) in invasively characterized heart failure with preserved ejection fraction (HFpEF). Subscribe to Eagle's Eye View
September 30 · 8 min
Whole Grain Intake & CV Health, Talfamidis & Recurrent Cardiovascular Events, Revascularization & Improved Cognition, Coronary Blood Flow in Women
In this week's View, Dr. Eagle looks at how higher whole-grain intake was associated with improvements in multiple cardiometabolic risk factors in a meta-analysis of randomized trials. He then examines how concomitant use of tafamidis or heart failure (HF) therapies did not modify the treatment benefit of vutrisiran on all-cause mortality and recurrent cardiovascular events, according to a HELIOS-B analysis, and follows that with a look in the case of patients with severe asymptomatic carotid artery stenosis, adding revascularization with either carotid artery stenting (CAS) or carotid endarterectomy (CEA) to intensive medical management (IMM) did not improve cognition compared with IMM alone, according to results from the CREST-2 randomized trials. Finally, Dr. Eagle explores how women in the CENTURY trial had higher coronary blood flow (CBF) than men while having a comparable burden of cardiovascular risk factors, similar treatment response and half the coronary events, offering a potential physiological explanation for the delayed clinical manifestation of coronary artery disease (CAD) in women. Subscribe to Eagle's Eye View
September 23 · 10 min
First Medical Contact, CV Toxicity and Antibody-Drug Conjugates, Extreme Heat & Blood Pressure, FinACAF & Lower Risk of ischemic Stroke
In this week's View, Dr. Eagle looks at a recent JACC: Advances Viewpoint that examines the challenges associated with implementing revisions to the definition of first medical contact (FMC) introduced in the 2025 ACC/AHA ACS Guideline and its implications for NCDR data collection. He then examines a cardiooncology primer on CV toxicity of antibody-drug conjugates (ADCs) in breast cancer and follows that with a look at extreme heat and blood press (BP) changes, especially among the elderly. Finally, Dr. Eagle explores the results of the FinACAF study that indicates patients with atrial flutter only (AFL-only) had a 40% lower risk of ischemic stroke than those with atrial fibrillation only (AFib-only). Subscribe to Eagle's Eye View
September 16 · 10 min
CV Subspecialty Training; a Novel Left Atrium Staging Framework; the (IL)-6 Inflammatory Biomarker, HF Risk & Diabetes
In this week's View, Dr. Eagle looks at a recent article on proposed changes to the current cardiovascular (CV) subspecialty training path. He then examines an article on a novel left atrium (LA) staging framework that stratifies new-onset atrial fibrillation risk in hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle explores the results of a Look AHEAD ancillary study on the inflammatory biomarker interleukin (IL)-6 that identified residual inflammatory risk of incident heart failure (HF) in patients with type 2 diabetes (T2D) and overweight/obesity. Subscribe to Eagle's Eye View
September 9 · 10 min
Top Five Trials from ESC 26: SINGLE-AF, REBOOT-PARADOX, ViVA, REACT, NOTION-4
In this week's View, Dr. Eagle looks at some of the important trials presented at this year's European Society of Cardiology (ESC) Congress. First, he evaluates the SINGLE-AF trial on DOAC therapy versus no anticoagulation in atrial fibrillation (AFib) with patients with intermediate stroke risk. Dr. Eagle then examines REBOOT-PARADOX and its study of the potential value of transcatheter aortic valve replacement (TAVR) in symptomatic patients with low-flow, low-gradient aortic stenosis. Next, Dr. Eagle covers ViVA, a randomized trial that looked at vericiguat for the treatment of coronary vasospasm, followed by a summary of the REACT trial that investigated the use of imaging to detect silent atherosclerosis in early adulthood. Finally, Dr. Eagle explores NOTION-4, which looks at short-term direct oral anticoagulant (DOAC) therapy and subclinical leaflet thickening after TAVR. Subscribe to Eagle's Eye View
September 2 · 8 min
: M-TEER, MR, & LV Dysfunction, Stress Perfusion CMR & CAD; Sacubutril/Valsartan, Cardiac Remodeling, and Non-Obstructive HCM.
In this week's View, Dr. Eagle evaluates how sacubitril/valsartan promotes cardiac remodeling, but not functional capacity, in nonobstructive hypertrophic cardiomyopathy. Next, he examines the prognostic value of stress perfusion cardiac magnetic resonance in patients with suspected coronary artery disease. Finally, Dr. Eagle explores a study on mitral transcatheter edge-to-edge repair (M-TEER) and its effectiveness for treatment of patients with ventricular functional mitral regurgitation (MR) and very severe left ventricular (LV) dysfunction. Subscribe to Eagle's Eye View
September 2 · 7 min
M-TEER, MR, & LV Dysfunction, Stress Perfusion CMR & CAD; Sacubutril/Valsartan, Cardiac Remodeling, and Non-Obstructive HCM.
In this week's View, Dr. Eagle evaluates how sacubitril/valsartan promotes cardiac remodeling, but not functional capacity, in nonobstructive hypertrophic cardiomyopathy. Next, he examines the prognostic value of stress perfusion cardiac magnetic resonance in patients with suspected coronary artery disease. Finally, Dr. Eagle explores a study on mitral transcatheter edge-to-edge repair (M-TEER) and its effectiveness for treatment of patients with ventricular functional mitral regurgitation (MR) and very severe left ventricular (LV) dysfunction. Subscribe to Eagle's Eye View
August 26 · 9 min
CAC, CRF & Dementia; Athletes & Arrhythmia; Vutrisaran & Amyloid Burden; NT0proBNP Screening & Heart Failure
In this week's View, Dr. Eagle looks at the relationship between lower cardiorespiratory fitness (CRF) and higher coronary artery calcium scores (CAC) and later-life dementia. He follows this with a look at a new State of the Art Review related to guidance on treating athletes with arrhythmia. He then offers a perspective on the use of vutrisiran in the treatment of amyloid burden. Finally, Dr. Eagle explores the TARTAN-HF study on NT-proBNP screening and its ability to identify undiagnosed heart failure (HF) among patients with diabetes. Subscribe to Eagle's Eye View
August 12 · 8 min
Antithrombotic Regimens after Valve-in-Vave TAVR; TAV vs. SAVR Outcomes in Low-Risk Patients; Sex Difference and Delayed Diagnosis on Acoramidis; Lifestyle Intervention and ANOCA
In this week's View, Dr. Eagle looks at the wide variation in antithrombotic regimens after valve-in-valve transcatheter aortic valve replacement (TAVR). Next, he examines PARTNER-3, a 7-year study on TAVR versus surgical aortic valve replacement (SAVR) outcomes in low-risk patients. He then offers a perspective on the effect of sex difference and delayed diagnosis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) from amyloidosis. Finally, Dr. Eagle explores the prospective SAMCRO trial which evaluates lifestyle intervention in addition to medical therapy in patients with invasively confirmed angina with no obstructive coronary artery disease (ANOCA). Subscribe to Eagle's Eye View
July 29 · 9 min
Venous Thromboembolism & Cancer; Influenza Vaccines & AFib; the DAPT-MVD Trial & Cutting PCI in CAD; the AC Expect Consensus Decision Pathway on HFpEF
In this week's View, Dr. Eagle looks at a post-hoc analysis of the API-CAT trial that showed recurrent venous thromboembolism (VTE) is uncommon but associated with poor short-term survival of patients with cancer-associated thrombosis. He follows with a look at an observational cohort study on how influenza vaccination is associated with lower risks of incident atrial fibrillation (AFib), then reviews evidence from the DAPT-MVD trial demonstrating that extended DAPT lowers the risk of cardiovascular events after percutaneous coronary intervention (PCI) in multivessel coronary artery disease. Finally, Dr. Eagle explores ACC's updated expert consensus decision pathway addressing the management of heart failure preserved ejection fraction (HFpEF). Subscribe to Eagle's Eye View
July 22 · 9 min
Age, BMI, & TAVR; Enhanced Radiation Protections in Cath Labs; Particulate Matter and CV Risk; the SUMMIT Trial & Tirzepatide.
In this week's View, Dr. Eagle looks at age, body mass index (BMI), and cardiovascular outcomes after transcatheter aortic valve replacement (TAVR). He follows this with an examination of a new consensus statement about enhanced radiation protection in cath labs, then offers a perspective on particulate matter in the environment and increased coronary heart disease risk. Finally, Dr. Eagle provides an analysis of the SUMMIT Trial, showing the benefit of tirzepatide for heart failure with preserved ejection fraction (HFpEF) both in women and men. Subscribe to Eagle's Eye View
July 15 · 10 min
Mechanical Leaflet Splitting and TAVR; Ambient Temperature & Marathons; AFib, PVI with PA & IRF; the SHaRE Registry as a Predictor of MACE
In this week's View, Dr. Eagle looks at the feasibility of mechanical leaflet splitting in high-risk patients undergoing valve-in-valve TAVR. He follows this with an examination of lower ambient temperature and it association with greater SCA risk at marathon races, then offers a commentary on two studies that provide new insights on the durability of pulmonary vein isolation (PVI) with pulsed field ablation (PA) vs radiofrequency ablation IRF) in patients with persistent atrial fibrillation (AFib). Finally, Dr. Eagle discusses the SHaRe Registry and its use in predicting major adverse cardiovascular events MACE for patients with mild hypertrophic cardiomyopathy (HCM). Subscribe to Eagle's Eye View
July 8 · 9 min
Guideline-Directed Medical Therapy & Atrial Fibrillation; Anti-Platelet Therapy & ASCVD; DOACs & Prevention of Thrombotic Events; Sugar-Sweetened Beverages and Fruit Juice & Hypertension
In this week's View, Dr. Eagle looks at withdrawing guideline-directed medical therapy (GDMT) for patients with atrial fibrillation (AF). He follows this with commentary on two important recently released ACC scientific statements: one on anti-platelet therapy for atherosclerotic cardiovascular disease (ASCVD), and the other examining the use of direct oral anticoagulants (DOACs) for primary and secondary prevention of thrombotic events. Finally, Dr. Eagle summarizes a recent longitudinal study on sugar-sweetened beverages and fruit juice and their potential relationship to the development of hypertension later in a young person's life. Subscribe to Eagle's Eye View
July 1 · 8 min
Genotype and Hypertrophic Cardiomyopathy; PARTNER 2A & TAVR 10 Years Later; Clopidogrel vs. Aspirin after PCI; LDL & Risk Assessment of ASCVD
In this week's View, Dr. Eagle looks at how genotype independently predicts heart failure outcomes in patients with hypertrophic cardiomyopathy (HCM). He then examines the ten-year follow-up of the PARTNER 2A trial and compares the transcatheter aortic valve replacement (TAVR) outcomes to results from the Partner 2 SAPIEN XT and SAPIEN 3 studies. He follows this with a report on how clopidogrel may offer a long-term edge over aspirin after percutaneous coronary intervention (PCI). Finally, Dr. Eagle summarizes HELIUS cohort findings demonstrating that LDL-C, Lp(a), and hsCRP provide complementary, independent insights for identifying long-term atherosclerotic cardiovascular disease (ASCVD) risk across diverse ethnic populations. Subscribe to Eagle's Eye View
June 24 · 9 min
Lifestyle Intervention, Metformin and Multimorbidity Risk in Prediabetes; Hypertension, Hyperlipidemia and Chronic Kidney Disease, Resistance Training & Myocardial Infarction
In this week's View, Dr. Eagle reviews 21-year follow-up data from the Diabetes Prevention Program (DPP), showing that lifestyle intervention—but not metformin—reduces multimorbidity risk in prediabetes. He also highlights low rates of hypertension and hyperlipidemia treatment among U.S. adults with cardiovascular-kidney-metabolic (CKM) syndrome, and summarizes evidence that resistance training, particularly when combined with aerobic exercise, is associated with a lower risk of cardiovascular (CV) disease, especially myocardial infarction, in women. Finally, he discusses the CAMERA-MRI II study in patients with atrial fibrillation and left ventricular systolic dysfunction (LVSD), where catheter ablation significantly improved left ventricular ejection fraction (LVEF) regardless of late gadolinium enhancement status. Subscribe to Eagle's Eye View
June 17 · 8 min
Race and Sex Disparities in Mitral Valve Edge-to-Edge Repair
In this week's View, Dr. Eagle highlights a study showing race and sex disparities in M-TEER outcomes, with Black patients presenting with more advanced disease, lower success, and higher heart failure readmissions than White patients, and women having lower success rates than men. He reviews the SOGALDI-PEF trial, where patients with low plasma renin levels experienced greater blood pressure reduction with spironolactone/dapagliflozin compared to dapagliflozin alone. Next, he discusses the FAVOR III trial, which found that QFR-guided percutaneous coronary intervention improved five-year outcomes versus angiography guidance, with most benefits occurring in the first two years. Lastly, Dr. Eagle examines two renal disease studies addressing optimal chronic kidney disease (CKD) GFR thresholds and the benefits of finerenone in CKD patients.
June 10 · 7 min
Impact of Semaglutide And Survival Outcomes In Patients With T2D and CKD
In this week's View, Dr. Eagle highlights several noteworthy developments shaping cardiovascular and renal care. He first examines the FLOW analysis, underscoring the benefits of semaglutide for patients with chronic kidney disease, with particular attention to its impact on both renal and cardiovascular outcomes. He then reviews a phase I study exploring an innovative therapeutic approach involving a single intravenous infusion—Verve-2—which targets PCSK9 expression in the liver and may represent a promising future strategy for treating familial hyperlipidemia. Finally, Dr. Eagle discusses recent findings on antihypertensive drug combinations, emphasizing those regimens that provide optimal efficacy while minimizing adverse effects that often lead to early treatment discontinuation.
June 3 · 9 min
Postpartum Cardiovascular Care; 'Low Risk' Chest Pain in the ER; Heart Failure Risk Detection & CV Outcomes with Implantable Devices
In this week's View, Dr. Eagle looks at recent research found in ACC's new expert decision pathway for postpartum cardiovascular care. He then offers insights from the ACC Chest Pain - MI Registry examining 'low risk' chest pain and its evaluation in the emergency departments. Next, a discussion of how negative patient outcomes were associated with late pericardial effusion post-left atrial appendage occlusion (LAAO) device implantation. Finally, Dr. Eagle summarizes the ALLEVIATE-HF trial that explored heart failure (HF) risk detection with an insertable cardiac monitor paired with a centrally coordinated nurse-led diuretic intervention. Subscribe to Eagle's Eye View

Showing 1–20 of 27 episodes